Key result
PCI shows no benefit over medical therapy for major cardiovascular events in isolated side branch ostial stenosis.
Why the study?
The optimal treatment strategy for isolated non-left main side branch ostial stenosis remains debated, with uncertainty about the comparative outcomes of medical therapy versus PCI.
Does percutaneous coronary intervention in addition to medical therapy reduce major adverse cardiovascular events compared to medical therapy alone in patients with isolated non-left main side branch ostial stenosis?
Cohort (n=357)
No
Does percutaneous coronary intervention in addition to medical therapy reduce major adverse cardiovascular events compared to medical therapy alone in patients with isolated non-left main side branch ostial stenosis?
In patients with isolated non-left main side branch ostial stenosis, optimal medical therapy appears to be a reasonable strategy as clinical outcomes are comparable to percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
No MACE reduction with PCI over medical therapy in isolated side branch ostial stenosis; leaves open need for randomized confirmation.
CĂl: StenĂłza ostia postrannĂ vÄtve (side branch, SB) je Äastou bifurkaÄnĂ lĂŠzĂ, pĹitom o optimĂĄlnĂ strategii jejĂ lĂŠÄby se stĂĄle vede diskuse. AÄkoli je ĂşÄinnost optimĂĄlnĂ farmakoterapie dobĹe znĂĄma, i nadĂĄle je srovnĂĄnĂ farmakoterapie a perkutĂĄnnĂ koronĂĄrnĂ intervence (PCI) pĹedmÄtem sporu. Metodika: Celkem bylo retrospektivnÄ hodnoceno 357 po sobÄ nĂĄsledujĂcĂch pacientĹŻ s izolovanou stenĂłzou ostia SB (klasifikace 0.0.1 podle Mediny). Pacienti byli rozdÄleni do dvou skupin; pacienti pouze s farmakoterapiĂ (n = 305) a pacienti podstupujĂcĂ PCI (n = 52). Revaskularizace cĂlovĂŠ tepny (target vessel revascularization, TVR), infarkt myokardu (IM) a mortalita byly hodnoceny jako zĂĄvaĹžnĂŠ neŞådoucĂ kardiovaskulĂĄrnĂ pĹĂhody (major adverse cardiovascular events, MACE). VĂ˝sledky: PrĹŻmÄrnĂ˝ vÄk pacientĹŻ byl 58,2 ± 10,3 roku. Sto dva pacientĹŻ (28,6 %) byly Ĺženy. DvÄ stÄ sedmdesĂĄt devÄt pacientĹŻ (78,2 %) mÄlo lĂŠzi na diagonĂĄlnĂ vÄtvi, zatĂmco 78 (21,8 %) jich mÄlo lĂŠzi na levĂŠ marginĂĄlnĂ vÄtvi. PomÄr stenĂłz SB (70 ± 16; 88 ± 13; p < 0,001) a dĂŠlka lĂŠze SB (7,5 ± 6,6; 14,7 ± 6,0; p < 0,001) byly vÄtĹĄĂ ve skupinÄ s PCI. Äastou metodou PCI byla implantace stentu do ostia SB (38 pacientĹŻ [73,1 %]). Mezi skupinami nebyly nalezeny ŞådnĂŠ statisticky vĂ˝znamnĂŠ rozdĂly v Äastosti TVR (1,3 % vs. 1,9 %; p = 0,277; farmakoterapie vs. PCI), incidenci IM (8,2 % vs. 7,7 %; p = 0,302; farmakoterapie vs. PCI), v mortalitÄ (10,2 % vs. 9,6 %; p = 0,095; farmakoterapie vs. PCI), ani v incidenci MACE (18,0 % vs. 15,4 %; p = 0,113; farmakoterapie vs. PCI). NavĂc Kaplanova-Meierova analĂ˝za dlouhodobĂŠho pĹeĹžitĂ nezjistila mezi skupinami ŞådnĂŠ rozdĂly v Äastosti TVR (log-rank p = 0,247), incidenci IM (log-rank p = 0,295), v mortalitÄ (log-rank p = 0,086) ani v incidenci MACE (log-rank p = 0,107). ZĂĄvÄry: U pacientĹŻ se stenĂłzou ostia postrannĂ vÄtve jinĂŠ cĂŠvy neĹž hlavnĂho kmene levĂŠ vÄnÄitĂŠ tepny se jako vhodnĂĄ a optimĂĄlnĂ lĂŠÄebnĂĄ strategie jevĂ farmakoterapie mĂsto PCI.
No takes yet. Share an insight, caveat, or question.
Kahraman et al. (2024) conducted a cohort in Isolated non-left main side branch ostial stenosis (n=357). Percutaneous coronary intervention (PCI) vs. Medical therapy alone was evaluated on Major adverse cardiovascular events (composite of target vessel revascularization, myocardial infarction, and all-cause death) (HR 1.852, 95% CI 0.865-3.964, p=0.113). Percutaneous coronary intervention did not reduce the incidence of major adverse cardiovascular events compared to medical therapy alone in patients with isolated non-left main side branch ostial stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: